Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial - Wikidata - wikimedia - TriplyDB

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

http://www.wikidata.org/entity/Q29618031

about

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells Targeted therapy for advanced renal cell carcinoma Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Updates of mTOR inhibitors A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma mTOR inhibitors in advanced renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma Pushing the envelope in the mTOR pathway: the second generation of inhibitors Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy State of the science: an update on renal cell carcinoma Targeting the mTOR signaling network for cancer therapy Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma MEK and PI3K inhibition in solid tumors: rationale and evidence to date Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Toward rapamycin analog (rapalog)-based precision cancer therapy Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Nonadherence to treatment protocol in published randomised controlled trials: a review Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Role of immunotherapy for renal cell cancer in 2011

P2860

Q21183974-E6C4797A-4D5D-436E-98A0-2AFDBA485FEC Q21198871-DC2B8FB9-1717-4367-A57C-2329DE127475 Q21260390-4248E29F-C464-4443-B864-CD92DD20D763 Q24242946-16896B7C-C4CD-489F-B89D-D656A9776DC9 Q24289425-23DFF5AC-0606-4652-AF9B-BE9E3FEC5182 Q24600932-2DB2DC1B-99A8-4D91-B789-22CBF672CD23 Q24606852-11706049-FF8F-4F93-AA20-1BBAF58833C3 Q24607170-8368A898-7FEB-4F28-91D5-9F0DDE999726 Q24607479-7D45FDFF-8998-49AB-8626-01EC6D7D1D7F Q24612127-9C13E5B1-DFE4-4FD6-921E-522CDF4BFE44 Q24613720-78ECB0B6-24ED-416C-BB8B-CDB48315E4B0 Q24622222-F75DFC57-3798-4E21-8EA6-DFA71C09A2DE Q24628724-E4EBBEB2-876C-4977-9E08-8D57818130A5 Q24630685-7D1B3108-31F1-404B-BBCF-313AF8B48BDC Q24658334-FEEA1C9A-6023-4E9A-BCA6-DC89AD5A3899 Q26738668-98EE1381-8934-409E-8EA5-985F7B94B45F Q26740594-5BA9758C-C09A-4F96-9342-26D9B3517981 Q26741450-1AC1490F-2E40-4482-BA86-842B141E8BB4 Q26747767-4DA7BA03-C097-47E6-A567-032CFF1213DA Q26749011-E8CA518E-8BBD-402C-8E69-D9496897BB23 Q26751155-671DE65E-E221-4335-B739-E2F11B97FB81 Q26751341-93DD9D5F-1F1D-4372-A293-367D864A6E3E Q26766240-F981DACE-C2C9-4204-8308-9F810115550C Q26772206-2ED39A71-23AE-4ED1-AADE-41DB6AEB449F Q26773653-24C2EBFE-280E-46AB-BB32-3D2ED5FBD3CA Q26775573-A76F82FD-264A-4DA3-9D02-8A0DD35F0E78 Q26775769-735DA73A-7206-4418-922F-9CF79CE8285F Q26786243-8925DDE2-6D61-47BA-B1AB-75B8648707F5 Q26795606-68A7F60F-C206-4BFE-9B29-CA50D8FFF1CF Q26801279-77597078-B936-4323-B309-BC44C5319EF7 Q26825321-F6B0BF7C-3CA0-4EA9-A30B-23608542C943 Q26827319-9AD31BCD-6587-41B0-B865-01D723F1EC19 Q26829652-54735C30-0B8B-4061-912E-999C4B75215B Q26829730-DF6D62C8-3C3D-42F1-94AC-B82FD8924D2C Q26830525-72852EA0-AE64-43E2-BD78-ACC88891C7C1 Q26830671-183B6870-9593-4D07-AE60-B7B60EF56F2B Q26851417-A5103FE1-BB5D-424C-843F-02E09497C6DB Q26852437-8957AA52-C1AC-476A-9EDF-8710E28248FF Q26852704-A668D0FE-F052-4024-A1E5-1A5A35D3C769 Q26853453-1B8E8EA1-397E-417C-85D5-54FF4A81BF2F

P2860

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

http://www.wikidata.org/entity/Q29618031

description

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

article publié dans la revue scientifique The Lancet

@fr

artículu científicu espublizáu en 2008

@ast

im August 2008 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 9 August 2008)

@en

wetenschappelijk artikel (gepubliceerd op 2008/08/09)

@nl

наукова стаття, опублікована в серпні 2008

@uk

مقالة علمية (نشرت في 9-8-2008)

@ar

ശാസ്ത്രപ്രബന്ധം

@ml

name

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@ast

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@en

type

label

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@ast

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@en

prefLabel

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@ast

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@en

P1433

Q29618031-8CAE5869-6E9C-4AB2-9F39-DA1717A72725

P1476

Q29618031-A8E734D8-6CB2-4875-A67E-3FCE1368BEFD

P2093

Q29618031-1561E85C-E634-40BA-9B76-C7047AEB7431

Q29618031-2E55178D-1F6B-4AC2-A564-0F3FB601D831

Q29618031-3C22A0A8-583D-4A52-94ED-F3548F800F0B

Q29618031-5F3E135C-A471-4480-A0F0-648148186D57

Q29618031-7AA8D29C-92A5-4099-87FF-E91BFCEFDBC4

Q29618031-80774CFD-7FC7-4841-867C-263F369B2D11

Q29618031-87775F58-3A03-4AAA-8450-C834832E2CE3

Q29618031-A54AB6A7-82C3-4341-9B36-002712EE674D

Q29618031-B8409397-8AFE-4FB2-AA74-4A2483674468

Q29618031-D75CF5EB-5251-41E3-B745-65F330437177

P304

Q29618031-93B55893-6B92-44D2-8A8D-4259AEB43AC3

P31

Q29618031-BE53348F-F522-4629-B2EB-2D5FAA9CF071

P3181

Q29618031-3D3A88D4-4D3A-4BA0-B8F2-DA576146B650

P356

Q29618031-BABB6F89-8C3F-421B-851A-6F6BB71679A7

P407

Q29618031-1B4B44F6-5962-48A2-86E5-596763C06C07

P433

Q29618031-552D47B8-C546-4A8B-8CFB-ADFB125F1C73

P478

Q29618031-7F3F242D-95C6-4A96-A829-177E3B7EC026

P50

Q29618031-1DBC9DEB-3AEF-4813-982A-324DD78AE8CD

Q29618031-F666FD90-5531-4D1D-84DD-985C82E99A48

Q29618031-FB98785D-CE6C-4ED9-A7D0-CE126D4BFE7B

P577

Q29618031-7C5F5255-9BE6-4B0A-9708-584F5005A371

P698

Q29618031-6EDB54AF-D11B-4BFE-8D7C-3A44F5FFF861

P921

Q29618031-4854B313-CFCA-4BCD-AE67-D5F140ACF37A

Q29618031-D9866F6A-E996-48CF-BBF9-BFF96268C9C9

P3181

P356

S0140-6736(08)61039-9

P1433

P1476

Efficacy of everolimus in adva ...... ebo-controlled phase III trial

@en

P2093

Andrea Kay

http://www.w3.org/2001/XMLSchema#string

Bernard Escudier

http://www.w3.org/2001/XMLSchema#string

David Lebwohl

http://www.w3.org/2001/XMLSchema#string

Gladys Urbanowitz

http://www.w3.org/2001/XMLSchema#string

John A Thompson

http://www.w3.org/2001/XMLSchema#string

Norbert Hollaender

http://www.w3.org/2001/XMLSchema#string

RECORD-1 Study Group

http://www.w3.org/2001/XMLSchema#string

Robert A Figlin

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Stéphane Oudard

http://www.w3.org/2001/XMLSchema#string

P304

449-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19195

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(08)61039-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9637

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18653228

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial